Replies to post #53467 on NorthWest Biotherapeutics Inc (NWBO)

[Ready4bluesky]

Flipper, how much longer before the Powers that be figure out how to resolve the issues that "haven't been helping the study" and those that can "wreck havoc on clinical trials"? Weeks, months, years? Is it even salvageable? The market thinks not. What do you think?

[Evaluate]

What's more, with Celldex, they mathematically have reached the median for both placebo and for control regarding both PFS and OS, if their presentation is accurate that the dmc recommendation is "seemingly imminent."

It means the DMC already have their final p values for both end points, but perhaps more important, it probably means they likely only have 10% or so that have not yet progressed.

So no wonder the CEO projects he's more interested in hazard ratio right now. It's the only significant stat left that he can affect through continuing the trial? --- Flipper

How do you come to above conclusions?
How many in the trial?
What mathematical median did they reach for "placebo & control" regarding PFS & OS?
How do you know?
Why does DMC recommendation need to be imminent for your assumptions to be correct?
How do you know they would already have their final p values for PFS and for OS?
How do you know they likely only have 10% or so that have not progressed yet?
Why exactly do you think the CEO is most interested in the hazard ratio? It sounded to me that their trial was designed to hit certain p values at the interims and at the final, and that it was looking like the p value was already looking pretty good .... but that the p value criterium to stop the trial at 2nd interim would be a tough nut to crack, but as trial continues with more results coming in from their patients regarding PFS & OS .... then waiting until trial completion might make most sense?